| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JUNE 2015. Refer to TA339: Omalizumab for previously treated chronic spontaneous urticaria for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | omalizumab (Xolair®) | |
| Formulation | 150 mg solution for injection | |
| Reference number | 1047 | |
| Indication | Add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1 antihistamine treatment |
|
| Company | Novartis Pharmaceuticals UK Ltd | |
| BNF chapter | Respiratory system | |
| Submission type | Non-submission | |
| Status | Superseded | |
| Ratification by Welsh Government | 23/05/2014 | |
| Date of issue | 27/05/2014 | |
| NICE guidance | TA339: Omalizumab for previously treated chronic spontaneous urticaria |
|